Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine

NCT ID: NCT04189367

Last Updated: 2020-06-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-20

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open-label randomized controlled trial of the efficacy of the integration of Traditional Chinese medicine (TCM) and western medicine based on TCM syndrome differentiation. The hypothesis is (1) TCM model can identify the primary and secondary type burning mouth syndrome (BMS); (2) TCM model can identify BMS after treatment with western medicine; (3) There is a positive effect of TCM in treating BMS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BMS patients will be classified into the primary type and secondary type according to the patients' clinical histories and laboratory examinations. The secondary BMS only includes nutritional deficiency, such as Vitamin B12, folate, iron, zinc. At first, the primary BMS patients are treated with 0.5\~1 mg clonazepam every day before sleep for 8 weeks. The secondary BMS patients are treated with vitamin B12, folate, iron and zinc according to the patient's nutritional deficiency status. Patients with no improvement or little improvement after the first stage of Western medicine management will be arranged to receive traditional Chinese medicine (TCM) therapy. All patients will receive the TCM model, including TCM doctor, automatic tongue diagnostic system (ATDS), and body constitutional questionnaire (BCQ), evaluations.

The results of this study are expected to understand whether adjuvant TCM treatment of BMS can improve treatment efficacy. The investigators will understand whether the constitution pattern may be a predictive indicator of efficacy for western BMS. The investigators will find a diagnostic indicator for the TCM model and apply it to the assessment of the prognosis of BMS patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burning Mouth Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Western medicine + TCM

1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
2. Blood test and physiological assessment, and do the TCM model.
3. Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
4. Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.
5. TCM therapy: one bag of "Qingre Liangkou Ningxin Fang", three times a day for 12 weeks.

Group Type EXPERIMENTAL

Traditional Chinese Medicine

Intervention Type DRUG

One bag of " Qingre Liangkou Ningxin Fang" at a time, three times a day for 12 weeks.

Western medicine

Intervention Type DRUG

Western medicine includes:

1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks
2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks

Western medicine

1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
2. Blood test and physiological assessment, and do the TCM model.
3. Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
4. Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.

Group Type ACTIVE_COMPARATOR

Western medicine

Intervention Type DRUG

Western medicine includes:

1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks
2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Traditional Chinese Medicine

One bag of " Qingre Liangkou Ningxin Fang" at a time, three times a day for 12 weeks.

Intervention Type DRUG

Western medicine

Western medicine includes:

1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks
2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TCM WM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who signed the informed consent
2. The clinical diagnosis was primary or secondary type BMS patient
3. ≥ 20-year-old
4. Female
5. Willing to take Traditional Chinese Medicine

Exclusion Criteria

1. History of an angiotensin-converting enzyme inhibitor (ACEI) taking
2. Autoimmune disease
3. Poor kidney function
4. Unwilling to take Traditional Chinese Medicine
5. Male
6. Participants who have been treated with TCM or Acupuncture within a month
7. Participants who have been treated with medicine for burning mouth syndrome
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Science and Technology, Taiwan

OTHER_GOV

Sponsor Role collaborator

Chang Gung Memorial Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MENG LING CHIANG, DDS

Director, Head of Oral Pathology and Oral Diagnosis, Principal Investigator, Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Meng-Ling Chiang, DDS,MS

Role: PRINCIPAL_INVESTIGATOR

Chang Gung Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chang Gung Memorial Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Meng-Ling Chiang, DDS,MS

Role: CONTACT

+8867135211 ext. 8212

Shun-Li Kuo, MD, MS

Role: CONTACT

+8863196200 ext. 2611

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Meng Ling Chiang

Role: primary

+8867135211 ext. 8212

References

Explore related publications, articles, or registry entries linked to this study.

Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician. 2002 Feb 15;65(4):615-20.

Reference Type BACKGROUND
PMID: 11871678 (View on PubMed)

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658. No abstract available.

Reference Type BACKGROUND
PMID: 23771276 (View on PubMed)

Jaaskelainen SK. Is burning mouth syndrome a neuropathic pain condition? Pain. 2018 Mar;159(3):610-613. doi: 10.1097/j.pain.0000000000001090.

Reference Type BACKGROUND
PMID: 29257770 (View on PubMed)

Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis. 2018 Apr;24(3):325-334. doi: 10.1111/odi.12660. Epub 2017 Mar 30.

Reference Type BACKGROUND
PMID: 28247977 (View on PubMed)

McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev. 2016 Nov 18;11(11):CD002779. doi: 10.1002/14651858.CD002779.pub3.

Reference Type BACKGROUND
PMID: 27855478 (View on PubMed)

Minguez-Sanz MP, Salort-Llorca C, Silvestre-Donat FJ. Etiology of burning mouth syndrome: a review and update. Med Oral Patol Oral Cir Bucal. 2011 Mar 1;16(2):e144-8. doi: 10.4317/medoral.16.e144.

Reference Type BACKGROUND
PMID: 21217613 (View on PubMed)

Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002779. doi: 10.1002/14651858.CD002779.pub2.

Reference Type BACKGROUND
PMID: 15674897 (View on PubMed)

Adamo D, Sardella A, Varoni E, Lajolo C, Biasotto M, Ottaviani G, Vescovi P, Simonazzi T, Pentenero M, Ardore M, Spadari F, Bombeccari G, Montebugnoli L, Gissi DB, Campisi G, Panzarella V, Carbone M, Valpreda L, Giuliani M, Aria M, Lo Muzio L, Mignogna MD. The association between burning mouth syndrome and sleep disturbance: A case-control multicentre study. Oral Dis. 2018 May;24(4):638-649. doi: 10.1111/odi.12807. Epub 2018 Mar 13.

Reference Type RESULT
PMID: 29156085 (View on PubMed)

Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome--a randomized double-blind placebo-controlled trial. J Oral Pathol Med. 2009 Mar;38(3):254-61. doi: 10.1111/j.1600-0714.2008.00735.x. Epub 2009 Jan 23.

Reference Type RESULT
PMID: 19175713 (View on PubMed)

Chang CM, Wu PC, Chiang JH, Wei YH, Chen FP, Chen TJ, Pan TL, Yen HR, Chang HH. Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study. J Ethnopharmacol. 2017 Jan 20;196:201-212. doi: 10.1016/j.jep.2016.12.016. Epub 2016 Dec 12.

Reference Type RESULT
PMID: 27974236 (View on PubMed)

Chang YY, Tsai YT, Lai JN, Yeh CH, Lin SK. The traditional Chinese medicine prescription patterns for migraine patients in Taiwan: a population-based study. J Ethnopharmacol. 2014 Feb 12;151(3):1209-1217. doi: 10.1016/j.jep.2013.12.040. Epub 2014 Jan 2.

Reference Type RESULT
PMID: 24389028 (View on PubMed)

Chen HY, Lin YH, Wu JC, Chen YC, Yang SH, Chen JL, Chen TJ. Prescription patterns of Chinese herbal products for menopausal syndrome: analysis of a nationwide prescription database. J Ethnopharmacol. 2011 Oct 11;137(3):1261-6. doi: 10.1016/j.jep.2011.07.053. Epub 2011 Aug 2.

Reference Type RESULT
PMID: 21824510 (View on PubMed)

Chen HY, Huang BS, Lin YH, Su IH, Yang SH, Chen JL, Huang JW, Chen YC. Identifying Chinese herbal medicine for premenstrual syndrome: implications from a nationwide database. BMC Complement Altern Med. 2014 Jun 27;14:206. doi: 10.1186/1472-6882-14-206.

Reference Type RESULT
PMID: 24969368 (View on PubMed)

Chen LL, Lin JS, Lin JD, Chang CH, Kuo HW, Liang WM, Su YC. BCQ+: a body constitution questionnaire to assess Yang-Xu. Part II: Evaluation of reliability and validity. Forsch Komplementmed. 2009 Feb;16(1):20-7. doi: 10.1159/000197770. Epub 2009 Feb 17.

Reference Type RESULT
PMID: 19295226 (View on PubMed)

Chen YL, Lee CY, Huang KH, Kuan YH, Chen M. Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan. J Ethnopharmacol. 2015 Aug 2;171:307-16. doi: 10.1016/j.jep.2015.05.045. Epub 2015 Jun 9.

Reference Type RESULT
PMID: 26068429 (View on PubMed)

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005 Jan;113(1-2):9-19. doi: 10.1016/j.pain.2004.09.012. No abstract available.

Reference Type RESULT
PMID: 15621359 (View on PubMed)

Femiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis. 2000 Sep;6(5):274-7. doi: 10.1111/j.1601-0825.2000.tb00138.x.

Reference Type RESULT
PMID: 11002408 (View on PubMed)

Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):557-61. doi: 10.1016/s1079-2104(98)90345-6.

Reference Type RESULT
PMID: 9830647 (View on PubMed)

Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope. 2012 Apr;122(4):813-6. doi: 10.1002/lary.22490. Epub 2012 Feb 16.

Reference Type RESULT
PMID: 22344742 (View on PubMed)

Hens MJ, Alonso-Ferreira V, Villaverde-Hueso A, Abaitua I, Posada de la Paz M. Cost-effectiveness analysis of burning mouth syndrome therapy. Community Dent Oral Epidemiol. 2012 Apr;40(2):185-92. doi: 10.1111/j.1600-0528.2011.00645.x. Epub 2011 Nov 1.

Reference Type RESULT
PMID: 22044166 (View on PubMed)

Hidaka T, Yonezawa R, Saito S. Kami-shoyo-san, Kampo (Japanese traditional medicine), is effective for climacteric syndrome, especially in hormone-replacement-therapy-resistant patients who strongly complain of psychological symptoms. J Obstet Gynaecol Res. 2013 Jan;39(1):223-8. doi: 10.1111/j.1447-0756.2012.01936.x. Epub 2012 Jul 6.

Reference Type RESULT
PMID: 22765925 (View on PubMed)

Hsu PC, Tsai YT, Lai JN, Wu CT, Lin SK, Huang CY. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014 Oct 28;156:358-64. doi: 10.1016/j.jep.2014.08.029. Epub 2014 Aug 29.

Reference Type RESULT
PMID: 25178949 (View on PubMed)

Imura H, Shimada M, Yamazaki Y, Sugimoto K. Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med. 2016 Mar;45(3):231-6. doi: 10.1111/jop.12350. Epub 2015 Aug 21.

Reference Type RESULT
PMID: 26293497 (View on PubMed)

Kuten-Shorrer M, Treister NS, Stock S, Kelley JM, Ji YD, Woo SB, Lerman MA, Palmason S, Sonis ST, Villa A. Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Aug;124(2):146-151. doi: 10.1016/j.oooo.2017.05.470. Epub 2017 May 11.

Reference Type RESULT
PMID: 28606830 (View on PubMed)

Lien AS, Jiang YD, Mou CH, Sun MF, Gau BS, Yen HR. Integrative traditional Chinese medicine therapy reduces the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus. J Ethnopharmacol. 2016 Sep 15;191:324-330. doi: 10.1016/j.jep.2016.06.051. Epub 2016 Jun 20.

Reference Type RESULT
PMID: 27340102 (View on PubMed)

Lee AL, Chen BC, Mou CH, Sun MF, Yen HR. Association of Traditional Chinese Medicine Therapy and the Risk of Vascular Complications in Patients With Type II Diabetes Mellitus: A Nationwide, Retrospective, Taiwanese-Registry, Cohort Study. Medicine (Baltimore). 2016 Jan;95(3):e2536. doi: 10.1097/MD.0000000000002536.

Reference Type RESULT
PMID: 26817897 (View on PubMed)

Lin JD, Chen LL, Lin JS, Chang CH, Huang YC, Su YC. BCQ-: a body constitution questionnaire to assess Yin-Xu. Part I: establishment of a provisional version through a Delphi process. Forsch Komplementmed. 2012;19(5):234-41. doi: 10.1159/000343580. Epub 2012 Oct 18.

Reference Type RESULT
PMID: 23128097 (View on PubMed)

Lin SK, Tsai YT, Lai JN, Wu CT. Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: a nationwide database study. J Ethnopharmacol. 2015 Feb 23;161:108-15. doi: 10.1016/j.jep.2014.12.015. Epub 2014 Dec 17.

Reference Type RESULT
PMID: 25527314 (View on PubMed)

Lin YC, Chang TT, Chen HJ, Wang CH, Sun MF, Yen HR. Characteristics of traditional Chinese medicine usage in children with precocious puberty: A nationwide population-based study. J Ethnopharmacol. 2017 Jun 9;205:231-239. doi: 10.1016/j.jep.2017.05.006. Epub 2017 May 10.

Reference Type RESULT
PMID: 28499829 (View on PubMed)

Lin YR, Wu MY, Chiang JH, Yen HR, Yang ST. The utilization of traditional Chinese medicine in patients with dysfunctional uterine bleeding in Taiwan: a nationwide population-based study. BMC Complement Altern Med. 2017 Aug 29;17(1):427. doi: 10.1186/s12906-017-1939-1.

Reference Type RESULT
PMID: 28851349 (View on PubMed)

Lo LC, Chen YF, Chen WJ, Cheng TL, Chiang JY. The Study on the Agreement between Automatic Tongue Diagnosis System and Traditional Chinese Medicine Practitioners. Evid Based Complement Alternat Med. 2012;2012:505063. doi: 10.1155/2012/505063. Epub 2012 Aug 8.

Reference Type RESULT
PMID: 22924055 (View on PubMed)

Lo LC, Cheng TL, Chiang JY, Damdinsuren N. Breast cancer index: a perspective on tongue diagnosis in traditional chinese medicine. J Tradit Complement Med. 2013 Jul;3(3):194-203. doi: 10.4103/2225-4110.114901.

Reference Type RESULT
PMID: 24716178 (View on PubMed)

Lo LC, Cheng TL, Chen YJ, Natsagdorj S, Chiang JY. TCM tongue diagnosis index of early-stage breast cancer. Complement Ther Med. 2015 Oct;23(5):705-13. doi: 10.1016/j.ctim.2015.07.001. Epub 2015 Jul 10.

Reference Type RESULT
PMID: 26365451 (View on PubMed)

Ma YC, Lin CC, Li CI, Chiang JH, Li TC, Lin JG. Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients. Semin Arthritis Rheum. 2016 Apr;45(5):596-603. doi: 10.1016/j.semarthrit.2015.09.006.

Reference Type RESULT
PMID: 26522135 (View on PubMed)

Park DM, Kim SH, Park YC, Kang WC, Lee SR, Jung IC. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations: multicenter, randomized, double blind, placebo controlled trial. J Ethnopharmacol. 2014 Dec 2;158 Pt A:11-7. doi: 10.1016/j.jep.2014.10.024. Epub 2014 Oct 23.

Reference Type RESULT
PMID: 25456420 (View on PubMed)

Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976 Nov;12(5):321-61. doi: 10.2165/00003495-197612050-00001.

Reference Type RESULT
PMID: 976134 (View on PubMed)

Puhakka A, Forssell H, Soinila S, Virtanen A, Roytta M, Laine M, Tenovuo O, Teerijoki-Oksa T, Jaaskelainen SK. Peripheral nervous system involvement in primary burning mouth syndrome--results of a pilot study. Oral Dis. 2016 May;22(4):338-44. doi: 10.1111/odi.12454. Epub 2016 Feb 26.

Reference Type RESULT
PMID: 26847146 (View on PubMed)

Qu Y, Gan HQ, Mei QB, Liu L. Study on the effect of Jia-Wei-Xiao-Yao-San decoction on patients with functional dyspepsia. Phytother Res. 2010 Feb;24(2):245-8. doi: 10.1002/ptr.2920.

Reference Type RESULT
PMID: 19610028 (View on PubMed)

Sun A, Lin HP, Wang YP, Chen HM, Cheng SJ, Chiang CP. Significant reduction of serum homocysteine level and oral symptoms after different vitamin-supplement treatments in patients with burning mouth syndrome. J Oral Pathol Med. 2013 Jul;42(6):474-9. doi: 10.1111/jop.12043. Epub 2013 Jan 9.

Reference Type RESULT
PMID: 23297780 (View on PubMed)

Sikora M, Verzak Z, Matijevic M, Vcev A, Siber S, Music L, Carek A. Anxiety and Depression Scores in Patients with Burning Mouth Syndrome. Psychiatr Danub. 2018 Dec;30(4):466-470. doi: 10.24869/psyd.2018.466.

Reference Type RESULT
PMID: 30439807 (View on PubMed)

Su YC, Chen LL, Lin JD, Lin JS, Huang YC, Lai JS. BCQ+: a body constitution questionnaire to assess Yang-Xu. Part I: establishment of a first final version through a Delphi process. Forsch Komplementmed. 2008 Dec;15(6):327-34. doi: 10.1159/000175938. Epub 2008 Dec 5.

Reference Type RESULT
PMID: 19142042 (View on PubMed)

Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, Matsushima E, Kubota T. Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances. Arch Gynecol Obstet. 2011 Oct;284(4):913-21. doi: 10.1007/s00404-010-1779-4. Epub 2010 Dec 1.

Reference Type RESULT
PMID: 21120510 (View on PubMed)

Tsai DS, Chang YS, Li TC, Peng WH. Prescription pattern of Chinese herbal products for hypertension in Taiwan: a population-based study. J Ethnopharmacol. 2014 Sep 29;155(3):1534-40. doi: 10.1016/j.jep.2014.07.047. Epub 2014 Aug 1.

Reference Type RESULT
PMID: 25091464 (View on PubMed)

Yang YH, Chen PC, Wang JD, Lee CH, Lai JN. Prescription pattern of traditional Chinese medicine for climacteric women in Taiwan. Climacteric. 2009 Dec;12(6):541-7. doi: 10.3109/13697130903060081.

Reference Type RESULT
PMID: 19905906 (View on PubMed)

Yu MC, Lin SK, Lai JN, Wei JC, Cheng CY. The traditional Chinese medicine prescription patterns of Sjogren׳s patients in Taiwan: a population-based study. J Ethnopharmacol. 2014 Aug 8;155(1):435-42. doi: 10.1016/j.jep.2014.05.049. Epub 2014 Jun 4.

Reference Type RESULT
PMID: 24905866 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMRPG3J6101

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB201802359A3C601

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.